ライフサイエンスコーパス: Tourette syndrome

1 ell palsy, normal pressure hydrocephalus, or Tourette syndrome).

2 cularly those involving motor systems (e.g., Tourette syndrome).

3 and behavioural expressions of Gilles de la Tourette syndrome.

4 e and effective intervention for adults with Tourette syndrome.

5 ole of the basal ganglia in causing tics and Tourette syndrome.

6 molecular and cellular mechanisms underlying Tourette syndrome.

7 the neurobiology, genetics and treatment of Tourette syndrome.

8 pression, obsessive-compulsive disorder, and Tourette syndrome.

9 n FSIs has been found in human patients with Tourette syndrome.

10 regions are important in the pathogenesis of Tourette syndrome.

11 sential blepharospasm, hemifacial spasm, and Tourette syndrome.

12 lse control is volitional tic suppression in Tourette syndrome.

13 ocus heterogeneity or a polygenic origin for Tourette syndrome.

14 and evaluated for a possible involvement in Tourette syndrome.

15 ol intake, frequency of drinking alcohol and Tourette syndrome.

16 sive compulsive disorder, schizophrenia, and Tourette syndrome.

17 or motor tics in the pathoneurophysiology of Tourette syndrome.

18 tor tics recapitulating the major symptom of Tourette syndrome.

19 major depressive disorder, schizophrenia and Tourette syndrome.

20 comorbid OCB than with tics in patients with Tourette syndrome.

21 for future studies of treatments for tics in Tourette syndrome.

22 ne targets for neuromodulation therapies for Tourette syndrome.

23 inhibit automatic behaviors, such as tics in Tourette syndrome.

24 ronto-striatal networks hyperconnectivity in Tourette syndrome.

25 tem to study how motor tics are generated in Tourette syndrome.

26 rders, especially schizophrenia, autism, and Tourette syndrome.

27 on in unmedicated patients with Gilles de la Tourette syndrome.

28 We currently lack an ideal animal model for Tourette syndrome.

29 gain in HIV infection, sleep disorders, and Tourette syndrome.

30 spired new research on functional anatomy of Tourette syndrome.

31 iology in schizophrenia, anxiety, autism and Tourette syndrome.

32 bipolar disorder to 14.2% h(2) decrease for Tourette syndrome.

33 predict or influence longitudinal outcome of Tourette syndrome.

34 rders associated with Huntington disease and Tourette syndrome.

35 proach could improve motor and vocal tics in Tourette syndrome.

36 d 131 human brains (44 neurotypical, 19 with Tourette syndrome, 9 with schizophrenia, and 59 with aut

37 lative to comparison subjects, patients with Tourette syndrome activated more strongly the frontal co

38 We studied 11 patients with Tourette syndrome and 11 healthy controls.

39 g was used to scan 120 participants (51 with Tourette syndrome and 69 comparison subjects) as they ei

40 cents aged 6 to 16 years with a diagnosis of Tourette syndrome and active tics causing distress or im

41 icantly associated with disinhibition, while Tourette syndrome and ADHD risk scores were not.

42 Motor tics are a cardinal feature of Tourette syndrome and are traditionally associated with

43 y experience with patients with Gilles de la Tourette syndrome and covers its definition and history

44 habitual behavioural control in Gilles de la Tourette syndrome and formally tested the hypothesis of

45 r, eye blinking, in children and adults with Tourette syndrome and in healthy comparison subjects.

46 ychotic-medicated patients with Gilles de la Tourette syndrome and matched controls.

47 ons contribute to movement disorders such as Tourette syndrome and obsessive compulsive disorder, in

48 ar stereotypies manifest in animal models of Tourette syndrome and obsessive compulsive disorder.

49 gton disease and other chorea syndromes, and Tourette syndrome and other chronic tic disorders.

50 the temporal properties of tics expressed in Tourette syndrome and other tic disorders have eluded cl

51 the abnormal striatal inhibition typical of Tourette syndrome and other tic disorders results in tic

52 motor tics resembling those expressed during Tourette syndrome and other tic disorders.

53 of haloperidol, one available treatment for Tourette syndrome and primarily a D2 receptor antagonist

54 odeling movement sequences and treatments in Tourette syndrome and related disorders.

55 on have been observed in human patients with Tourette syndrome and rodent models of dystonia.

56 th anxiety, depression, anorexia nervosa and Tourette syndrome and was negatively associated with inf

57 nding of the genetics and pathophysiology of Tourette syndrome and will be crucial for future large-s

58 zheimer and Parkinson diseases, Gilles de la Tourette syndrome, and addiction.

59 r, attention-deficit/hyperactivity disorder, Tourette syndrome, and adolescent depression.

60 s has also been implicated in schizophrenia, Tourette syndrome, and bipolar disorder.

61 bsessive-compulsive disorder, schizophrenia, Tourette syndrome, and cognitive ability were calculated

62 hyperactivity in pre-SMA/SMA in both OCD and Tourette syndrome, and evidence that pre-SMA is a potent

63 associated with tic disorders, most commonly Tourette syndrome, and neurometabolic conditions, such a

64 accompanies tics may be particularly high in Tourette syndrome, and this may contribute to less effic

65 Treatment options for Tourette syndrome are expanding with novel pharmacologic

66 regulated in ischemic stroke, migraine, and Tourette syndrome are shown to be associated with distin

67 the other neuropsychiatric symptoms seen in Tourette syndrome are thought to have an organic basis,

68 uclear families, which were collected by the Tourette Syndrome Association International Consortium f

69 s conducted on 77 sib pairs collected by the Tourette Syndrome Association International Consortium f

70 d a replication sample of 186 trios from the Tourette Syndrome Association International Consortium o

71 ders involving compulsive behaviors, such as Tourette syndrome, attention-deficit hyperactivity disor

72 Tics in Tourette syndrome begin in childhood, peak in early adol

73 ficit/Hyperactivity Disorder, Schizophrenia, Tourette Syndrome, Bipolar Disorder, or persons at high

74 re the neural basis of tics in patients with Tourette syndrome by using event-related functional MRI

75 ession was studied in 22 adult subjects with Tourette syndrome by using functional magnetic resonance

76 forward model updating in young adults with Tourette syndrome', by Kim et al. (doi:10.1093/brain/awy

77 g in frontal and parietal lobes in groups of Tourette syndrome children relative to controls.

78 Tourette syndrome/chronic tic disorder (TS/CT) and obses

79 rs of a 3-generation pedigree with 7 showing Tourette syndrome/chronic tic phenotype (TS-CTD) were ev

80 update summarizes progress in understanding Tourette syndrome clinical characteristics, etiology, an

81 in YGTSS-TTS for low-dose deutetrabenazine, Tourette Syndrome Clinical Global Impression score, Tour

82 Key secondary end points included changes in Tourette Syndrome-Clinical Global Impression, Tourette S

83 nglia networks in patients with Gilles de la Tourette syndrome compared with controls.

84 N = 37 female) with a confirmed diagnosis of Tourette syndrome completed the premonitory urges for ti

85 tual behaviour in patients with Gilles de la Tourette syndrome correlated with greater structural con

86 recently argued that the presence of tics in Tourette syndrome could result in a blurring of any subj

87 Tourette syndrome/CT and OCD cluster in families.

88 Mean time since Tourette syndrome diagnosis was 3.3 (2.8) years, and mea

89 A rare genetic form of Tourette syndrome due to L-histidine-decarboxylase mutat

90 riatal activity is increased in persons with Tourette syndrome during the inhibition of eye blinks.

91 ssive-compulsive disorder, anorexia nervosa, Tourette syndrome), F2) psychotic disorders (including b

92 and latent class analyses were conducted in Tourette syndrome families and replicated in an independ

93 Polygenic risk scores derived from a Tourette syndrome genome-wide association study (GWAS) w

94 mary outcome variable was total score on the Tourette Syndrome Global Scale.

95 Here we demonstrate that while the Tourette syndrome group were equally accurate, and no mo

96 iability were significantly predicted by the Tourette syndrome group's clinical severity scores.

97 Gilles de la Tourette Syndrome (GTS) is a chronic tic disorder, chara

98 Gilles de la Tourette syndrome (GTS) is a complex neuropsychiatric di

99 Gilles de la Tourette syndrome (GTS) is a neurodevelopmental disorder

100 Gilles de la Tourette syndrome (GTS) is a potentially debilitating ne

101 Gilles de la Tourette syndrome (GTS) is characterized by multiple mot

102 erlying the involuntary tics of Gilles de la Tourette syndrome (GTS) remains unknown.

103 e concordant for a diagnosis of Gilles de la Tourette syndrome (GTS).

104 ied in a family suffering from Guilles de la Tourette syndrome (GTS).

105 An individual diagnosed with Tourette syndrome has been described carrying a constitu

106 tions, such as major depressive disorder and Tourette syndrome, have more limited, but promising resu

107 select cases of severe, treatment-refractory Tourette syndrome; however, patient responses are variab

108 g the translocation exhibit features seen in Tourette syndrome including motor tics, vocal tics, and

109 Tourette syndrome is a childhood-onset neuropsychiatric

110 Tourette syndrome is a chronic neurodevelopmental disord

111 Gilles de la Tourette syndrome is a clinically heterogeneous disorder

112 Tourette syndrome is a developmental neurological condit

113 Tourette syndrome is a neurodevelopmental disorder chara

114 Tourette syndrome is a neurodevelopmental disorder chara

115 Tourette syndrome is a neurodevelopmental disorder commo

116 Tourette syndrome is a neuropsychiatric disorder charact

117 Tourette syndrome is a prototypic neuropsychiatric disor

118 Evidence suggests that Tourette syndrome is characterized by an increase in dop

119 Evaluating and treating Tourette syndrome is complex, in part due to the heterog

120 Enhanced multi-component behaviour in Tourette syndrome is likely based on an enhanced ability

121 The underlying pathophysiology of Tourette syndrome is not fully understood, but recent re

122 Phenotypic heterogeneity in Tourette syndrome is partly due to complex genetic relat

123 ropsychiatric conditions: Parkinson disease, Tourette syndrome, major depressive disorder, and obsess

124 e needed to further understand their role in Tourette syndrome management.

125 the gamma-aminobutyric acid-ergic system in Tourette syndrome may conceivably underlie the symptoms

126 nsistent with the view that individuals with Tourette syndrome may experience a reduction in the prec

127 nterventive treatment for medical refractory Tourette syndrome, may reduce tics by affecting striatal

128 ehaviour was collected from 15 patients with Tourette syndrome (mean age = 30.40 +/- 11.10) and 15 he

129 y due to complex genetic relationships among Tourette syndrome, obsessive-compulsive disorder (OCD),

130 forms of neuropsychiatric disease, including Tourette syndrome, obsessive-compulsive spectrum disorde

131 METHOD: Assessments for Tourette syndrome, OCD, and ADHD symptoms were conducted

132 Assessments for Tourette syndrome, OCD, and ADHD symptoms were conducted

133 itability and polygenic load associated with Tourette syndrome, OCD, and ADHD were estimated.

134 Severe forms of Tourette syndrome or chronic tic disorder (TS/CTD) may i

135 associated with a subsequent risk of OCD and Tourette syndrome or chronic tic disorder (TS/CTD).

136 in diseases such as parkinsonism, dystonia, Tourette syndrome, or schizophrenia.

137 variety of neurological disorders including Tourette Syndrome, Parkinson's disease and schizophrenia

138 e Syndrome Clinical Global Impression score, Tourette Syndrome Patient Global Impression of Impact sc

139 ourette Syndrome-Clinical Global Impression, Tourette Syndrome-Patient Global Impression of Impact, a

140 sal ganglia and thalamus are disinhibited in Tourette syndrome patients.

141 The symmetry phenotype correlated with Tourette syndrome polygenic load and was present in othe

142 s, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumatic stress disorder, or ps

143 ntion-deficit hyperactivity disorder (ADHD), Tourette syndrome, post-traumatic stress disorder, or ps

144 peractivity disorder, autism, depression and Tourette syndrome, predicted psychiatric symptoms throug

145 Mothers of Tourette syndrome probands had high rates of symmetry (4

146 mena were found to have important impacts on Tourette syndrome quality of life.

147 mpact, and Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life Activities of Daily Li

148 score, and Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life Activities of Daily Li

149 on Depression Rating Scale, the Gilles de la Tourette Syndrome-Quality of Life Scale, and the Global

150 g that this phenotype may reflect additional Tourette syndrome (rather than OCD) genetic liability th

151 This survey of recent literature addressing Tourette syndrome reflects clinical and laboratory findi

152 of movements is impaired in individuals with Tourette syndrome, relative to a matched group of typica

153 ns such as obsessive-compulsive disorder and Tourette syndrome remain uncertain.

154 The majority of adult patients with Tourette syndrome report experiencing premonitory urges

155 he substantia nigra, Parkinson's disease and Tourette syndrome, show gender differences and age-relat

156 ictors of patient responses to therapies for Tourette syndrome, such as specific networks modulated d

157 development of neuromodulation therapies for Tourette syndrome that could use a closed-loop-based app

158 fied two heritable endophenotypes related to Tourette syndrome that cross traditional diagnostic boun

159 c interneurons are reported in patients with Tourette syndrome, the normal functions of these interne

160 trabenazine in children and adolescents with Tourette syndrome, the primary efficacy end point was no

161 trabenazine in children and adolescents with Tourette syndrome, the primary efficacy end point was no

162 Compared with 273 patients with Tourette syndrome, those with PMDs resembling tics were

163 To investigate the transmission of Tourette syndrome (TS) and associated disorders within f

164 psychiatric conditions, including some, like Tourette syndrome (TS) and attention deficit hyperactivi

165 lities are implicated in the pathogenesis of Tourette syndrome (TS) and chronic multiple tics.

166 ity of behavior therapy for individuals with Tourette syndrome (TS) and chronic tic disorder (CTD) is

167 or therapy is a recommended intervention for Tourette syndrome (TS) and chronic tic disorder (CTD), b

168 Tic disorders, including Tourette syndrome (TS) and chronic tic disorders (CTDs),

169 Tourette syndrome (TS) has a well-established genetic ba

170 g symptoms of otherwise treatment-refractory Tourette syndrome (TS) has been documented in several pu

171 Previous studies of brain structure in Tourette syndrome (TS) have produced mixed results, and

172 responsive' deep brain stimulation (DBS) for Tourette syndrome (TS) in a National Institutes of Healt

173 The etiology of Tourette syndrome (TS) involves disturbances in the stru

174 nce that the pathophysiology of Gilles de la Tourette syndrome (TS) involves structural and functiona

175 Tourette syndrome (TS) is a childhood-onset neurodevelop

176 Tourette syndrome (TS) is a childhood-onset neuropsychia

177 Tourette syndrome (TS) is a childhood-onset tic disorder

178 Tourette syndrome (TS) is a chronic neurologic disorder

179 Tourette syndrome (TS) is a common, chronic neuropsychia

180 Tourette syndrome (TS) is a complex childhood neurodevel

181 Tourette syndrome (TS) is a developmental disorder chara

182 Tourette syndrome (TS) is a developmental neurological d

183 Tourette syndrome (TS) is a developmentally regulated ne

184 Tourette syndrome (TS) is a highly heritable neuropsychi

185 Tourette syndrome (TS) is a model neuropsychiatric disor

186 Tourette syndrome (TS) is a neurodevelopmental disorder

187 Tourette syndrome (TS) is a neurodevelopmental disorder

188 Tourette syndrome (TS) is a neuropsychiatric disorder ch

189 Tourette syndrome (TS) is a neuropsychiatric disorder ch

190 Tourette syndrome (TS) is a neuropsychiatric disorder wi

191 Because Tourette syndrome (TS) is a paroxysmal disorder, symptom

192 Tourette syndrome (TS) is an inherited developmental neu

193 Tourette syndrome (TS) is characterized by high rates of

194 Tourette syndrome (TS) is characterized by multiple moto

195 Tourette syndrome (TS) is characterized by tics, sensori

196 Gilles de la Tourette syndrome (TS) is characterized by tics, which a

197 e is considerable evidence that Gilles de la Tourette syndrome (TS) is due to frontal-striatal dysfun

198 Tourette syndrome (TS) is often found comorbid with othe

199 The pathophysiology of Tourette syndrome (TS) is thought to involve disturbance

200 It remains unclear if individuals with Tourette syndrome (TS) or chronic tic disorder (CTD) hav

201 Tourette syndrome (TS) prominently involves dopaminergic

202 We analyzed rare CNVs in Tourette syndrome (TS) to identify novel risk regions an

203 e investigated the role of the cerebellum in Tourette syndrome (TS), a condition defined by the prese

204 Autism spectrum disorder (ASD), Tourette syndrome (TS), and attention-deficit/hyperactiv

205 om of the classic neuropsychiatric disorder, Tourette syndrome (TS), and constitute an example of dis

206 lia and cortical targets in individuals with Tourette syndrome (TS), but less is known regarding the

207 ctural finding in the brain of patients with Tourette syndrome (TS), but the cellular abnormalities t

208 y risk-conferring common genetic variants in Tourette syndrome (TS), requiring the adoption of altern

209 as raised whether patients with Gilles de la Tourette syndrome (TS), who show tic-like movements, are

210 area (SMA) has been associated with tics in Tourette syndrome (TS).

211 investigate this conjecture in children with Tourette syndrome (TS).

212 select cases of severe, treatment-refractory Tourette syndrome (TS).

213 s are likely involved in the pathogenesis of Tourette syndrome (TS).

214 Slit and Trk-like 1) as a candidate gene for Tourette Syndrome (TS).

215 orbidity: autism spectrum disorder (ASD) and Tourette syndrome (TS).

216 d to obsessive-compulsive disorder (OCD) and Tourette syndrome (TS).

217 acute stress can worsen symptom severity in Tourette syndrome (TS); however, the neurobiological und

218 domised controlled trials; n=605), eight for Tourette syndrome (two randomised controlled trials; n=3

219 improved by plasma exchange (mean change on Tourette syndrome unified rating scale of 49%).

220 Tourette syndrome was associated with increased risk of

221 e disorder (OCD) or tic disorders, including Tourette syndrome, were randomly assigned treatment with

222 ently been implicated in the pathogenesis of Tourette syndrome, whereas motor and sensorimotor cortic

223 ldren and adolescents (aged 6-16 years) with Tourette syndrome with active tics causing distress or i

224 opsychology, and the effects of Gilles de la Tourette syndrome with studies showing that the quality

225 the model also shows the utility of casting Tourette syndrome within a system-level perspective rath